ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
ClearPoint Neuro (NASDAQ:CLPT), a global device, cell, and gene therapy-enabling company focused on brain and spine navigation, has scheduled its Q4 and full-year 2024 financial results release for February 26, 2025, after market close.
The company will host a live conference call at 4:30 p.m. Eastern time on the same day to review the results. Investors and analysts can participate via telephone at (877) 407-9034 (U.S./Canada) or (201) 493-6737 (International). A replay will be available until March 25th, 2025, accessible by calling (877) 660-6853 (U.S./Canada) or (201) 612-7415 (International) with conference ID 413671. An online archive will also be available on the company's investor website.
ClearPoint Neuro (NASDAQ:CLPT), un'azienda globale specializzata in dispositivi, cellule e terapie geniche per la navigazione del cervello e della colonna vertebrale, ha programmato il rilascio dei risultati finanziari per il Q4 e l'intero anno 2024 per il 26 febbraio 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica in diretta alle 16:30 ora orientale nello stesso giorno per esaminare i risultati. Investitori e analisti possono partecipare telefonicamente al numero (877) 407-9034 (U.S./Canada) o (201) 493-6737 (Internazionale). Una registrazione sarà disponibile fino al 25 marzo 2025, accessibile chiamando (877) 660-6853 (U.S./Canada) o (201) 612-7415 (Internazionale) con ID conferenza 413671. Un archivio online sarà inoltre disponibile sul sito web per investitori dell'azienda.
ClearPoint Neuro (NASDAQ:CLPT), una empresa global que habilita dispositivos, células y terapias génicas enfocadas en la navegación del cerebro y la columna vertebral, ha programado la publicación de sus resultados financieros para el Q4 y el año completo 2024 para el 26 de febrero de 2025, después del cierre del mercado.
La empresa realizará una conferencia telefónica en vivo a las 4:30 p.m. hora del Este el mismo día para revisar los resultados. Los inversores y analistas pueden participar por teléfono al (877) 407-9034 (EE.UU./Canadá) o (201) 493-6737 (Internacional). Una repetición estará disponible hasta el 25 de marzo de 2025, accesible llamando al (877) 660-6853 (EE.UU./Canadá) o (201) 612-7415 (Internacional) con el ID de conferencia 413671. También habrá un archivo en línea disponible en el sitio web de inversores de la empresa.
ClearPoint Neuro (NASDAQ:CLPT), 뇌 및 척추 내비게이션에 중점을 둔 글로벌 기기, 세포 및 유전자 치료 지원 회사가 2024년 4분기 및 연간 재무 결과 발표를 2025년 2월 26일 시장 마감 후로 예정했습니다.
회사는 같은 날 동부 표준시 오후 4:30에 결과를 검토하기 위한 라이브 컨퍼런스 콜을 개최할 예정입니다. 투자자 및 분석가는 (877) 407-9034 (미국/캐나다) 또는 (201) 493-6737 (국제)로 전화에 참여할 수 있습니다. 녹음은 2025년 3월 25일까지 이용 가능하며, (877) 660-6853 (미국/캐나다) 또는 (201) 612-7415 (국제)로 전화하고 회의 ID 413671을 입력하면 접근할 수 있습니다. 회사의 투자자 웹사이트에서도 온라인 아카이브가 제공될 예정입니다.
ClearPoint Neuro (NASDAQ:CLPT), une entreprise mondiale spécialisée dans les dispositifs, les cellules et les thérapies géniques pour la navigation cérébrale et vertébrale, a prévu la publication de ses résultats financiers pour le Q4 et l'année complète 2024 le 26 février 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique en direct à 16h30, heure de l'Est le même jour pour examiner les résultats. Les investisseurs et les analystes peuvent participer par téléphone au (877) 407-9034 (États-Unis/Canada) ou au (201) 493-6737 (International). Un enregistrement sera disponible jusqu'au 25 mars 2025, accessible en appelant le (877) 660-6853 (États-Unis/Canada) ou le (201) 612-7415 (International) avec l'identifiant de conférence 413671. Une archive en ligne sera également disponible sur le site web des investisseurs de l'entreprise.
ClearPoint Neuro (NASDAQ:CLPT), ein globales Unternehmen, das Geräte, Zell- und Gentherapien für die Navigation im Gehirn und Rückenmark ermöglicht, hat die Veröffentlichung seiner Q4- und Jahresergebnisse 2024 auf den 26. Februar 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Live-Konferenzschaltung abhalten, um die Ergebnisse zu überprüfen. Investoren und Analysten können telefonisch unter (877) 407-9034 (USA/Kanada) oder (201) 493-6737 (International) teilnehmen. Eine Wiederholung wird bis zum 25. März 2025 verfügbar sein, erreichbar unter (877) 660-6853 (USA/Kanada) oder (201) 612-7415 (International) mit der Konferenz-ID 413671. Ein Online-Archiv wird ebenfalls auf der Investorenseite des Unternehmens zur Verfügung stehen.
- None.
- None.
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close.
Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until March 25th, 2025, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, both of which have been filed with the Securities and Exchange Commission, and the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2025. The Company does not assume any obligation to update these forward-looking statements.
Contact Information
Danilo D'Alessandro
Chief Financial Officer
ir@clearpointneuro.com
(888) 287-9109 ext. 3
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire
FAQ
When will ClearPoint Neuro (CLPT) release its Q4 and full-year 2024 earnings?
How can investors join ClearPoint Neuro's (CLPT) Q4 2024 earnings call?
Until when will ClearPoint Neuro's (CLPT) Q4 2024 earnings call replay be available?
Where can I find ClearPoint Neuro's (CLPT) Q4 2024 earnings webcast archive?
